The complete 30- and 90-day results of LEVO-CTS, a large randomized multicenter clinical trial, will provide insight into the efficacy and safety of levosimendan in reducing short-term morbidity and mortality in high-risk patients undergoing cardiac surgery with CPB.

Keywords: ACC17, ACC Annual Scientific Session, Aortic Valve, Cardiac Output, Low, Cardiac Surgical Procedures, Cardiopulmonary Bypass, Coronary Artery Bypass, Cost-Benefit Analysis, Hydrazones, Mitral Valve, Myocardial Infarction, Pyridazines, Renal Replacement Therapy, Stroke Volume

< Back to Listings